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Abstract. More than one mechanism may contribute to disease susceptibility in tuberculosis, 
viz., major histocompatability complex (MHC) restriction phenomenon, spectrum of immune 
reactivity/cytokine profile and epidemiology induced anergy. Experiments from our laboratories 
revealed that (i) human leucocyte antigen D-related allele 2 (HLA DR2) predispose for a more 
severe form of pulmonary tuberculosis encoding a high responder status, (ii) spectrum of immune 
reactivity to mycobacteria is 'innate', and it is demonstrable in healthy individuals from endemic 
area, (iii) there is no correlation between the purified protein derivative (PPD) response and 
peptide responses, (iv) once a person is high responder to P16 and P38 derived peptides (6/22), 
he/she (whether a patient or control) is a high responder for a wide range of mycobacterial 
peptides and (v)majority of the T-cell clones generated in vitro, to peptide 16·3 (amino acids 
21-40) of 16 kA a mycobacterial antigen, in an HLA DR2 positive healthy individual is HLA DR 
restricted, permissive and of Th1 phenotype. The results suggested that MHC class II restriction 
play a role in peptide recognition and the immune response. Nonetheless the outcome and 
specificity of the immune reactivity and the resultant disease pathogenesis may depend on the 
promiscuity of peptide recognition and cytokine profiles. 
 
Keywords. MHC restriction; mycobacterial diseases; immune reactivity; responder status; 
peptides; cytokines. 
 
 
 
1. Introduction 
 
The mechanism of association of HLA with diseases is still an enigma: this is more so with 
mycobacterioses, other chronic infections and parasitic diseases. In recent times, there is 
evidence for a stronger association of HLA DR2 with pulmonary tuberculosis (PTB) 
(Bothamley et al 1989; Khomenko et a/c 1990; Brahmajothi et al 1991). Many earlier studies 
showed associations with different HLA alleles in both class I and class II loci. One study 
on northern Indian population showed a nominal association with HLA DR2 (cf. 
Pitchappan 1990). Genome scan analysis of affected sib-pairs of diabetes using microsatel-
lite markers revealed that, HLA alleles contribute to 54% of disease pathogenesis and the 
rest is accounted by three other genes (Davies et al 1994). A similar kind of approach is 
warranted in mycobacterioses. Nonetheless one need to understand the immunological 
mechanisms that predispose for mycobacterioses for a better therapy and prevention. 
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There are many studies that evaluated both the HLA and immunological mechanisms 
in tuberculosis and leprosy (Nath et al 1980; Brahmajothi 1990; Rani et al 1992; 
Mehra et al 1995). Our study showed a strong HLA DR2 association with far advanced PTB 
(Brahmajothi et al 1991). Further, the existence of a spectrum of immune reactivity in healthy 
individuals has also been described by us for the first time (Pitchappan et al 1991). This has now 
been confirmed in Indonesian and Brazilian populations (Bothamley et al 1992; Fonseca et al 
1992). However, the HLA association and spectrum of reactivity may be two independent 
mechanisms. In this paper we present our observations on these aspects. 
 
2. Materials and methods 
 
Patients attending Govt. Rajaji Hospital, were enrolled, informed consent obtained 
and studied. Controls were drawn from hospital staff, students and staff of our 
 
Figure 1. Association of HLA DR2 with pulmonary tuberculosis. One hundred and seventy 
eight patients (PTB) and 273 controls (CTL) were studied for their HLA and sputum acid fast 
bacilli (AFB) and % HLA frequency calculated. HLA DR2 showed a significant relative risk. 
Patients were classified based on the presence of AFB in their sputum smear and culture (SP 
 N sputum negative; SP P, sputum positive) and % DR2 calculated. The sputum positive 
patients were further stratified, based on the number of AFB in their sputum smear, bacterial 
count in culture and based on the radiological lesions. Three categories were identified viz. 
+ (mild), + + (moderate) and + + + (far advanced) and DR2 frequency calculated and 
presented in the histogram. The results were similar in all the three methods of classification. 
The number above each bar represents the relative risks in the respective group: note that the 
relative risk was the highest in the + + + AFB category. 
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university. Serological typing of HLA was done by conventional two stage microlym-
phocytotoxicity assay (Terasaki and McClelland 1964). Allelic typing of HLA was done 
by (PCR-SSP) polymerase chain reaction-sequence specific primers and sequence 
specific oligo probes (SSOP) techniques (Olerup and Zetterquist 1992). Lymphocyte 
transformation test (LTT) assays and T-cell cloning was done following standard 
procedures (Mosmann et al 1986; Street et al 1990). Monoclonal antibodies employed 
were commercial ones and peptides were synthesized based on the known sequences of 
16 and 38 kDa antigens of Mycobacterium tuberculosis. Standard statistical methods 
were employed to analyse the data (Snedecor and Cochran 1968), employing the 
software developed for immunogenetic studies (Pitchappan and Arulraj 1989). 
 
3. Results and discussion 
 
3.1  HLA DR2 association 
 
Figure 1 presents the data on the distribution of HLA DR2, a high risk allele, in various 
subgroups of patients with pulmonary tuberculosis. While % frequency of HLA DR2 was 
27 in controls, it was 41 in PTB patients. On further stratification of patient samples, in 
sputum positive it was 57%, and in far advanced among them, it was 76. This suggested 
that if a person is infected and if that individual posses HLA DR2, his/her chances of 
developing a more severe, sputum positive ( + + + ), culture positive ( + + +) and 
radiologically far-advanced PTB is greater than other alleles (cf. Brahmajothi 1990; 
Brahmajothi et al 1991). Further patients with HLA DR2 showed higher antibody levels 
 
Figure 2. HLA DR2 and serum antibodies. Anti-HSP-70 (IgG) antibodies were estimated by 
ELISA in DR2 and non-DR2 patients. The results are presented as 0·2 OD class interval 
starting from 0·0–0·2. The Y axis represents the number of patients in each OD class.Note that 
more number of DR2 patients showed higher OD classes. 
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Table 1. HLA DR2 association with pulmonary tuberculosis in different populations. 
Cf. Pitchappan (1990) for a compilation of the earlier works on HLA association and showed a significant 
DR2 association. 
aBoathamley et al 1989, bKhomenko et al 1990, 'Brahmajothi et al 1991. 
Pts, patients; Ctl, controls; % PF phenotype frequency x 100; RR, relative risk; EF, etiological fraction; 
SP +, sputum positive; SP — , sputum negative; HR, high responders; EB, association transcend ethnic 
barriers. N, No; Y, yes. 
 
Figure 3. Spectrum of immune reactivity in sputum positive and sputum negative patients. 
Anti-H37Rv antibodies of IgG isotype of sputum positive and sputum negative patients were 
plotted against their respective Mantoux induration diameter. Note the differences in the slope 
of these two regression lines. 
 
than non-DR2 particularly in anti-HSP7O (figure 2) and in anti-PPD (Brahmajothi et al 
1991). There are two other studies confirming the HLA DR2 association (table 1): all these 
studies suggested that HLA DR2 correlates to a high responder status irrespective of 
mycobacterial antigen preparation used. Further, our study and Russian study confirmed 
that the HLA DR2 association transcend ethnic barriers (table 1). 
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3.2   Spectrum of immune reactivity 
 
We provide evidence that the spectrum of immune reactivity [two types of immunity 
viz., cell mediated (CMI) and humoral (HI)], demonstrable in patients with leprosy 
and tuberculosis, exists in healthy hospital contacts (Pitchappan et al 1991). This 
has now been confirmed and extended to healthy populations in Indonesia and Brazil 
(Bothamley et al 1992; Fonseca et al 1992). This inverse correlation (of CMI and HI) 
was observed in both sputum positive and negative patients as well. Nonetheless 
there was a quantitative and qualitative difference between these two patient groups 
(figure 3). This spectrum of immune reactivity correlated to the recovery of patients 
by chemotherapy and to the drug resistant statuses. The early converters possessed 
a good CMI but low antibody levels and the patients with drug resistant bacilli 
possessed a poor CMI and an elevated antibody level (Horton 1995; V Brahmajothi, 
R M Pitchappan, C N Paramasivan, K Rajaram, U Sankarkumar and R Prabhakar, 
unpublished results). In other words patients with a good CMI have a better prognosis. 
One may need to examine whether the good HI in poor prognostic groups are related 
to antibodies against drug resistant organisms: our study however has not answered 
this question directly. Nonetheless it is possible that the drug resistant organisms 
induce a higher levels of antibody leading to a more severe damage and persistence and 
therefore the delay in recovery by chemotherapy. 
In recent times immunity against mycobacterial infections is thought to depend on 
HLA class II restricted Thl cells (Ottenhoff 1996). Both type one (Thl cells) and type 
two (Th2 cells) cytokines have been reported in many tuberculosis and leprosy patients 
(Barnes et al 199O; Misra et al 1995). Cytokine profile of PBL and cells in the lesions of 
leprosy patients from India has revealed the presence of both indiscriminate (Th0) and
polarized (Th1 or Th2) T-cell subsets, in both tuberculoid leprosy (TL) and lepromatous 
leprosy (LL) patients. Further, no difference in the pattern of cytokine secretions 
between peripheral blood lymphocytes (PBL) and lesional lymphocytes and various 
mycobacterial antigens have been identified (Misra et al 1995). Though the skewing of 
T-cell subsets and their cytokine profile may be an important mechanism in the 
pathology of mycobacterial diseases, their role in susceptibility to the disease needs to 
be evaluated. It is possible that the spectrum of immune reactivity observed in healthy 
individual from endemic areas is the outcome of their cytokine profile (i.e., their 
Th1/Th2 status to the antigen in question) and this might decide the course of the 
resulting susceptibility, immunity and pathology. The proposition raises another 
interesting question whether the Th 1 or Th2 response to a given antigen/epitope is 
inherent (innate), and whether it can be skewed in an endemic area. 
 
 
 
3.3   High and low responder status to peptides 
 
In order to study the role of MHC restriction in disease pathogenesis, lymphocyte 
transformation test (LTT) responses of patients and controls to selected mycobacterial 
peptides were studied and correlated to their MHC class II (HLA DRB1, DRB5, DQA 
and DQB) haplotypes, assigned by PCR-SSP typing. There was no correlation between 
any given haplotype and allele to either high or low response to any particular peptide 
studied. Rather a high responder to a peptide irrespective of DR2 status, always 
responded high to many peptides, studied (figure 4) but not to PPD. To a descending 
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Figure 4. LT response of DR2 and non-DR2 PTB patients and controls to various mycobacterial 
peptides. LTT responses were studied in microplates following conventional methods and tritiated 
thymidine incorporation assays. Mycobacterial peptides (M. tub) 38A, 38G, 381, 16·3, 16.12 and PPD 
were studied in DR2 positive patients (N = 11), non-DR2 patients (11) and controls (14). Each data is 
the average of triplicate. The X-axis represents various individuals and they were arranged in the 
descending order of the PPD response (refer figure 5) and Y-axis counts per min. Note that if an 
individual responds to a given peptide, he/she responds to the same extent for other peptides studies 
 as well: nonetheless this did not correlate to the PPD response. 
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Figure 5. Comparison of PPD and PHA/Con A responses in DR2 and non-DR2 patients. 
Ten numbers of DR2 patients, 11 non-DR2 patients and 14 controls were studied for their 
proliferative responses to PPD, PHA and Con A (each data is the average of triplicate). The 
data on these samples were arranged on a descending order of PPD response and their PHA 
and ConA responses plotted. Note that PHA and Con A responses were higher at both the 
extremes of PPD responses compared to median responders. Thus the PPD responses did not 
correlate to PHA and Con A responses.
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Figure 6.   MHC restriction of T-cell clones generated from an HLA-DR15/DR9 hetero-
zygote healthy individual. Nineteen Th clones were generated in response to peptide 16·3 in
bulk culture and limiting dilution analysis. These clones were tested for their peptide 16·3
dependant proliferation in LTT assay, in the presence of monoclonal antibodies to HLA-
DR, HLA-DQ or HLA-DP. Proliferations of 12 clones were suppressed by anti-DR mon-
oclonal antibodies, five by anti-DP and two by anti-DQ thus identifying their MHC class II
restriction status. Of the 12 DR restricted clones eight were promiscuous and four,
monogamous (see figure 7).
 
order of LTT response to PPD, photohaemagglutinin (PHA) and Concanavalin-A 
(ConA) curves was bimodal, both in patients and controls (figure 5). The two polar 
groups of LTT response with higher PHA stimulation might be qualitatively different 
from one another and compared to the median responders. 
 
3.4 T-cell cloning studies 
 
Nineteen T-cell clones were generated against peptide 16·3, in a normal HLA 
DR15/DR9 heterozygous healthy donor. Of these clones 63% was HLA DR restric 
ted. Majority of these DR restricted clones (72·7%) were promiscuous in nature, 
i.e., they recognized the peptides presented by antigen presenting cells (APC) of either 
HLADR15 or DR9, the parental alleles (figure 6) (N Javed, Sara Deacock, 
R Wilkinson, R M Pitchappan and Ivanyi, unpublished results). Twenty-six percent of 
the clones generated were restricted by HLA DP4 (parental HLA DP) and 10% by
DQ2 (parental HLA DQ) and all of them were monogamous. The MHC restriction was 
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Figure 7. Promiscuity in MHC restriction. T-cell clones were presented with the peptide 16·3 
by various antigen presenting cells [homozygous epstein bar virus (EB V) cell lines with 
different HLA DR]. The antigen presenting cells (APCs) were pulsed with the peptide, 
presented to the clones and proliferation of the clones studied in a tritiated thymidine 
incorporation assay. The clones responded only when the peptide was presented by the 
respective restricting elements, i.e., one parental MHC (HLA DR15, DR9, D Q2 or DP4). If the 
clone was HLA DR15 restricted, it proliferated only when it was presented with the peptide by 
an APC carrying HLA DR15. However 72.7% of the DR restricted clones (42% of the total 
clones) recognized the peptide and proliferated when the peptides were presented by APCs 
carrying either HLA DR 15 or HLA DR9, indicating the promiscuity of these clones. Note that 
these clones did not know to recognize the peptides when presented by APCs carrying other 
than these two parental HLA DR alleles. All the DP and DQ restricted clones were 
monogamous, i.e., recognized the peptide in the context of any one of the parental alleles. 
 
evaluated by blocking the LTT response with HLA DR, DQ and DP locus specific 
monoclonal antibodies (figure 7). The study further revealed that majority (75%) of DR 
restricted, promiscuous clone were of Thl phenotype. The study revealed that (i) in 
response to a single peptide 16·3 in vitro, many clones can be generated (recall/memory 
response), (ii) each clone is restricted by one or the other MHC class II alleles of the host, 
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(iii) the HLA DR restricted clones were the predominant one, presumably easily inducible 
by the mycobacterial antigen in question and (iv) many HLA DR restricted clones were 
promiscuous in nature. Thus the disease may be the outcome of the interac-
tions of all these clones in vivo, and the genetics of the host may play a predominant role in
deciding whether the disease will manifest and progress in an infected (sub-clinically) host.
 
4. Conclusion 
 
The mechanism of association of HLA DR2 and the spectrum of immune reactivity in 
tuberculosis might be two parallel but independent mechanisms. During an immune 
response (in vitro), clones restricted by various MHC loci with different cytokine profile 
can be generated. The existence of high or low responder status to many mycobacterial 
peptides but not to PPD suggests that MHC diversity, mycobacterial peptides 
generated in a given milieu genetic, T-cell receptor (TCR) repertoire, epidemiology and 
cytokine profile, all may decide the disease susceptibility. Identifying the combinations 
of these factors leading to disease/protection is a challenging problem to immu-
nologists. 
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